Fyr offers an EV‑Omics (EVO) platform that enriches disease‑associated extracellular vesicles from a standard blood draw using its proprietary SPARCs technology, then applies multi‑omic (genomics, transcriptomics, proteomics) profiling and AI‑driven analytics to generate detailed molecular snapshots of disease. This enables pharmaceutical, biotech, and clinical research customers to discover robust biomarkers, design smarter trials, and support precise patient stratification and therapy monitoring without invasive tissue biopsies.
Funding
Funding not disclosed
Founders
Product
Problem
Current liquid biopsy approaches struggle to capture disease-relevant molecular information because extracellular vesicles (EVs) from diseased cells are a tiny fraction of the total EV population in blood, making it difficult to obtain reliable protein and RNA biomarkers for diagnosis, patient stratification, and treatment monitoring.
Solution
Fyr’s EV‑Omics (EVO) platform uses its proprietary Selective Protein Affinity Reagent Chemistries (SPARCs) to enrich disease‑associated EV subpopulations from a standard peripheral blood draw. The enriched EVs are then profiled across genomics, transcriptomics, and proteomics, generating a multi‑omic molecular snapshot of the patient’s disease state. AI‑enabled analytics integrate these data to identify biomarkers, support trial design, and guide therapy selection and monitoring. By converting a simple blood sample into a detailed, dynamic view of disease biology, Fyr enables more precise patient care from screening through treatment response assessment.
Target Audience
Primary customers are pharmaceutical and biotech companies developing diagnostics or therapeutics, as well as clinical research organizations seeking high‑resolution biomarkers for patient selection and monitoring.
Features
- SPARCs technology selectively isolates EVs linked to specific diseases, improving signal‑to‑noise for downstream analysis
- Multi‑omic profiling (DNA, RNA, protein) of enriched EVs provides comprehensive molecular insight
- AI‑driven data integration and biomarker discovery pipelines accelerate target identification and patient stratification
- Minimal invasive sampling using standard peripheral blood draws eliminates the need for surgical biopsies
- Cloud‑based analytics platform delivers actionable reports for clinicians and researchers